CN101928330B - New compound and application thereof - Google Patents

New compound and application thereof Download PDF

Info

Publication number
CN101928330B
CN101928330B CN 200910053905 CN200910053905A CN101928330B CN 101928330 B CN101928330 B CN 101928330B CN 200910053905 CN200910053905 CN 200910053905 CN 200910053905 A CN200910053905 A CN 200910053905A CN 101928330 B CN101928330 B CN 101928330B
Authority
CN
China
Prior art keywords
compound
preparation
fermented liquid
carried out
elutriant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN 200910053905
Other languages
Chinese (zh)
Other versions
CN101928330A (en
Inventor
陈代杰
罗敏玉
黄鹤
戈梅
魏维
阮林高
杨晟
朱丽
姜卫红
夏兴
杨志钧
李秋爽
王天娇
殷瑜
杨天
金文翔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Laiyi Biomedical Research And Development Center LLC
Zhejiang Medicine Co Ltd Xinchang Pharmaceutical Factory
Original Assignee
Shanghai Laiyi Biomedical Research And Development Center LLC
Zhejiang Medicine Co Ltd Xinchang Pharmaceutical Factory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Laiyi Biomedical Research And Development Center LLC, Zhejiang Medicine Co Ltd Xinchang Pharmaceutical Factory filed Critical Shanghai Laiyi Biomedical Research And Development Center LLC
Priority to CN 200910053905 priority Critical patent/CN101928330B/en
Publication of CN101928330A publication Critical patent/CN101928330A/en
Application granted granted Critical
Publication of CN101928330B publication Critical patent/CN101928330B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides a new compound and an application thereof. The compound comprises the structure as shown in formula (I), four-bit hydroxyl of glycosyl on hydroxy benzyl of six-bit amino acid of a peptide framework of the compound is an axial bond, and the compound is obtained through fermentation of CGMCC No. 3053. The compound has good antibacterial activity, thereby having very important significance for developing new antibacterial drugs.

Description

A kind of novel compound and application thereof
Technical field
The invention belongs to biological technical field, specifically, relate to a kind of novel compound and application thereof.
Background technology
Vancomycin is to be obtained by Amycolatopsis orientalis (Amycolatopsisorientalis) fermentation that separates in Indonesia's soil in 1956, it is the choice drug that clinical treatment methicillin-resistant staphylococcus aureus (methicillin-resistantStaphylococcus aureus, MRSA) infects.But the continuous use along with vancomycin, streptococcus aureus descends to some extent to the susceptibility of vancomycin, this will produce serious threat to clinical anti-infective therapy, therefore, it is extremely urgent that searching can improve the second generation of glycopeptide antibiotics of vigor to Resistant strain, simultaneously, but the recombinant bacterial strain that the preparation fermentative production is improved the second generation of glycopeptide antibiotics of vigor to Resistant strain also becomes an important research topic, also has same urgency.
Summary of the invention
The allos replacement operator of present inventor by glycosyltransferase gene among the Vancomycine producing fungus A.orientalis HCCB10007 is carried out, obtained the new Amycolatopsis orientalis bacterial strain of a strain, and in the fermented liquid of this strain Amycolatopsis orientalis, found a kind of novel compound.
Therefore, primary and foremost purpose of the present invention is, a kind of novel compound is provided.
Second purpose of the present invention is, the preparation method of the compound shown in the said structure formula (I) is provided.
The 3rd purpose of the present invention provides the application of this compound.
Novel compound provided by the present invention has with the structure shown in the following formula (I):
Figure G2009100539054D00021
Wherein: four hydroxyls of glycosyl on the benzyl hydroxyl of peptide backbone six amino acids (OH is such as 1 sign in the structural formula) are axial bond.
According to one embodiment of present invention, the compound shown in the described formula (I) obtains by fermentation strain CGMCCNo.3053.
According to a preferred embodiment of the present invention, the preparation method of described compound also comprises the step of fermented liquid being carried out separation and purification; Particularly, described purification procedures is as follows:
With macropore low-pole resin filtrate is carried out dynamic adsorption, carry out gradient elution with the ethanol-water solution that contains 0.005% hydrochloric acid, and collection ethanol: water is 6: 4 elutriant, then with activated carbon decolorizing, carry out the medium pressure liquid chromatography chromatography after concentrated, again to contain 0.3%NaH 2PO 4The methanol-water solution gradient wash-out of buffering salt, it is concentrated to collect main elutriant, and the wash-out concentrated solution that at last medium pressure liquid chromatography is prepared is with macropore low-pole resin absorption, with the methanol-water solution gradient wash-out that contains 0.001% hydrochloric acid, collect methyl alcohol: water is 6: 4 elutriant, desalination.
According to the present invention, fermented liquid carried out also comprising before the separation and purification fermented liquid carried out pretreated step that particularly, described pre-treatment step is as follows:
Fermented liquid is transferred pH3~4 with HCl, removes by filter mycelium.
Compound shown in the formula provided by the invention (I) has good anti-microbial activity, thereby can be used for preparing antibacterials.
Compound provided by the invention all has good anti-microbial activity for the various clinical pathogenic bacterium, and therefore the exploitation for new antibacterials has very important significance.
Description of drawings
Fig. 1 is the MS collection of illustrative plates of LYV07ww03.
Fig. 2 is LYV07ww03 1H NMR (Nuclear Magnetic Resonance) spectrum figure.
Fig. 3 is LYV07ww03 13C NMR (Nuclear Magnetic Resonance) spectrum figure.
Fig. 4 is the Cosy NMR (Nuclear Magnetic Resonance) spectrum figure of LYV07ww03.
Fig. 5 is the Noesy NMR (Nuclear Magnetic Resonance) spectrum figure of LYV07ww03.
Fig. 6 is the Tocsy NMR (Nuclear Magnetic Resonance) spectrum figure of LYV07ww03.
Fig. 7 is the Hsqc NMR (Nuclear Magnetic Resonance) spectrum figure of LYV07ww03.
Fig. 8 is the Hmbc NMR (Nuclear Magnetic Resonance) spectrum figure of LYV07ww03.
Fig. 9 is the chemical structural formula of LYV07ww03.
The engineering bacteria that the present invention obtains has been submitted on May 6th, 2009 and has been positioned at Pekinese China Committee for Culture Collection of Microorganisms common micro-organisms center (CGMCC) preservation, and preserving number is CGMCC No.3053.
Embodiment
Below in conjunction with specific embodiment, the invention will be further described.Should be understood that following examples are only for explanation the present invention but not for limiting scope of the present invention.
Embodiment 1, bacterial strain preparation
The allos replacement operator of contriver by glycosyltransferase gene among the Vancomycine producing fungus A.orientalis HCCB10007 is carried out, namely from Amycolatopsis balhimyceticus NRRL B-24207, angle and get its glycosyltransferase gene and replaced the glycosyltransferase gene of vancomycin by the method for conjugal transfer, thereby obtained the new bacterial strain of a strain.
This bacterial strain has been submitted on May 6th, 2009 and has been positioned at Pekinese China Committee for Culture Collection of Microorganisms common micro-organisms center (CGMCC) preservation, and preserving number is CGMCC No.3053.
Embodiment 2, fermentation culture
In CGMCC NO.3053 access seed culture medium, in 28 ℃, 220rpm cultivates 40-48h.Then, under aseptic condition, cultured seed liquor is changed in the fermentation shake flask with 8% inoculum size, in 28 ℃, 220rpm cultivates 115-120h, the results fermented liquid.
Embodiment 3, tunning separation and purification
3.1, fermentation liquor pretreatment
Fermented liquid is transferred pH3~4 with HCl, removes by filter mycelium, collects filtrate.
3.2, separation and purification
The separation purification method that provides among the referenced patent US5843437, the separation and purification fermented liquid, concrete purification condition is as follows:
HP-20 carries out dynamic adsorption to filtrate with macropore low-pole resin, carry out gradient elution with the ethanol-water solution that contains 0.005% hydrochloric acid, collect ethanol-water solution (6: 4) elutriant, then with activated carbon decolorizing, carry out the medium pressure liquid chromatography chromatography after concentrated, again to contain 0.3%NaH 2PO 4The methanol-water solution gradient wash-out of buffering salt, it is concentrated to collect main elutriant, and the wash-out concentrated solution that at last medium pressure liquid chromatography is prepared adsorbs with HP-20, with the methanol-water solution gradient wash-out that contains 0.001% hydrochloric acid, collect methyl alcohol: water is 6: 4 elutriant, desalination, drying.
With the product called after LYV07ww03 that obtains.
Embodiment 4, the LYV07ww03 structure determines
LYV07ww03 is carried out mass spectrometric detection, the result as shown in Figure 1, according to MS collection of illustrative plates shown in Figure 1, the molecular weight of LYV07ww03 is 1285.
By LYV07ww03 one-dimensional nuclear magnetic resonance wave spectrum (Fig. 2~3) and two dimensional NMR wave spectrum (Fig. 4~8) are resolved, determine the chemistry ownership of each carbon atom and hydrogen atom signal, confirm that its structure is similar, only slightly variant on six glycosyl configurations to ChloroorienticinC (two products that glycosyl hydrolase is sloughed on the phenolic hydroxyl group of Chloroeremomycin four amino acids).Wherein, the chemical shift of four hydrogen atoms is 3.43ppm on six glycosyls, shows as unimodal, coupling constant is less than 4Hz, and because adjacent five hydrogen atoms are axial bond, then four hydrogen atoms can only be equatorial bonds, four hydroxyls are axial bonds, and namely six of LYV07ww03 glycosyls are osamine base through the ages.
According to analysis result, obtain the chemical structural formula of LYV07ww03, specifically as shown in Figure 9, wherein, four hydroxyls (OH is shown in the structural formula 1) of glycosyl are axial bond on the benzyl hydroxyl of peptide backbone six amino acids of LYV07ww03.
Through retrieval, there are no the report of this compound, namely LYV07ww03 is a kind of novel compound in the prior art.
Embodiment 5, the LYV07ww03 Determination of Antibacterial Activity
With reference to the method that provides in the Pharmacopoeia of the People's Republic of China (version in 2005), detect the anti-microbial activity of LYV07ww03, wherein, the bacterial strain of use and LYV07ww03 are as shown in table 1 to the antibiotic dosage of described bacterial strain.
Table 1, detect the anti-microbial activity with bacterial strain and LYV07ww03
# Test bacterial strain character LYV07ww03 (MIC value)
1 Vancomycin-resistant enterococcus 128μg/ml
2 Vancomycin-resistant enterococcus 64μg/ml
3 Faecalis 0.5μg/ml
4 MRSA 0.5μg/ml
5 MRSA 0.25μg/ml
6 MRSA 0.5μg/ml
7 MRSA 1μg/ml
8 MRSA 0.5μg/ml
9 MRSA 0.5μg/ml
10 MRSA 0.5μg/ml
11 MRSA 0.5μg/ml
12 MRSA 0.5μg/ml
13 MRSA 0.5μg/ml
14 MRSA 0.5μg/ml
According to the result of table 1, the compound (LYV07ww03) shown in the formula provided by the invention (I) all has good anti-microbial activity for the various clinical pathogenic bacterium.
In sum, the compound shown in the formula provided by the invention (I) all has good anti-microbial activity for the various clinical pathogenic bacterium, therefore can be used for preparing antibacterials, has wide development prospect.

Claims (7)

1. a compound is characterized in that, described compound has the structure shown in the formula (I):
Figure FSB00001090581400011
Wherein: four hydroxyls of glycosyl are axial bond on the benzyl hydroxyl of peptide backbone six amino acids of described compound.
2. the preparation method of compound as claimed in claim 1 is characterized in that, described compound obtains by CGMCC No.3053 fermentation, and described method also comprises the step of fermented liquid being carried out separation and purification, and described purification procedures is as follows:
With macropore low-pole resin filtrate is carried out dynamic adsorption, carry out gradient elution with the ethanol-water solution that contains 0.005% hydrochloric acid, and collection ethanol: water is 6: 4 elutriant, then with activated carbon decolorizing, carry out the medium pressure liquid chromatography chromatography after concentrated, again to contain 0.3%NaH 2PO 4The methanol-water solution gradient wash-out of buffering salt, it is concentrated to collect main elutriant, and the wash-out concentrated solution that at last medium pressure liquid chromatography is prepared is with macropore low-pole resin absorption, with the methanol-water solution gradient wash-out that contains 0.001% hydrochloric acid, collect methyl alcohol: water is 6: 4 elutriant, desalination.
3. preparation method as claimed in claim 2 is characterized in that, described macropore low-pole resin is HP-20.
4. preparation method as claimed in claim 2 is characterized in that, also comprises drying step after the described desalination step.
5. preparation method as claimed in claim 2 is characterized in that, also comprises before fermented liquid is carried out separation and purification fermented liquid is carried out pretreated step.
6. preparation method as claimed in claim 5 is characterized in that, described pre-treatment step is as follows:
Fermented liquid is transferred pH3~4 with HCl, removes by filter mycelium.
7. compound as claimed in claim 1 is for the preparation of the application of antibacterials.
CN 200910053905 2009-06-26 2009-06-26 New compound and application thereof Active CN101928330B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200910053905 CN101928330B (en) 2009-06-26 2009-06-26 New compound and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200910053905 CN101928330B (en) 2009-06-26 2009-06-26 New compound and application thereof

Publications (2)

Publication Number Publication Date
CN101928330A CN101928330A (en) 2010-12-29
CN101928330B true CN101928330B (en) 2013-10-16

Family

ID=43367799

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200910053905 Active CN101928330B (en) 2009-06-26 2009-06-26 New compound and application thereof

Country Status (1)

Country Link
CN (1) CN101928330B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102690331B (en) * 2011-03-23 2015-05-20 浙江医药股份有限公司新昌制药厂 Monosaccharide glycopeptide derivative, pharmaceutical composition, preparation method and purpose thereof and preparation method of intermediate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1315961A (en) * 1998-12-23 2001-10-03 先进医药公司 Glycopeptide derivatives and pharmaceutical compositions containing same
CN101222933A (en) * 2005-02-28 2008-07-16 诺瓦蒂斯疫苗和诊断公司 Semi-synthetic glycopeptides with antibiotic activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1315961A (en) * 1998-12-23 2001-10-03 先进医药公司 Glycopeptide derivatives and pharmaceutical compositions containing same
CN101222933A (en) * 2005-02-28 2008-07-16 诺瓦蒂斯疫苗和诊断公司 Semi-synthetic glycopeptides with antibiotic activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Naoki Tsuji等.New glycopeptides antibiotics: II. The isolation and structures of chloroorienticins.《The Journal of Antibiotics》.1988,第41卷(第10期),1506-1510.
New glycopeptides antibiotics: II. The isolation and structures of chloroorienticins;Naoki Tsuji等;《The Journal of Antibiotics》;19881031;第41卷(第10期);1506-1510 *

Also Published As

Publication number Publication date
CN101928330A (en) 2010-12-29

Similar Documents

Publication Publication Date Title
CN101928331B (en) New compound and application thereof
US8338372B2 (en) Dehydroxy vancomycin, the preparation, pharmaceutical composition and the use
CN113544137A (en) Separation and purification method of vancomycin analogue
CN101628931B (en) Antitumor antibiotics, pharmaceutically acceptable salts thereof, preparation method thereof and use thereof
CN101928330B (en) New compound and application thereof
CN106801078B (en) Method for producing norvancomycin through fermentation
CN115974672A (en) Novel diketone compound and application thereof in antibacterial drugs
CN103146594B (en) Sorangiumcellulosum strain and application thereof to synthesis of epothilone
CN102703352B (en) Strain and method for preparing glucosyl apigenin through glycosylation in nonaqueous phase
US8742135B1 (en) Compound amycolamicin, method for producing the same, and use of the same
CN101701230A (en) Method for improving output of anticancer anthraquinone compound generated by Fusarium proliferatum via utilizing different vaccination ways
CN115109023A (en) Macrolide compound FWYZ52-A, and fermentation strain, fermentation method and application thereof
CN106167494A (en) Halogenation II type polyketide compound, preparation method and applications
CN107226845B (en) Compound YT-011 against multiple drug-resistant bacteria and preparation method thereof
US20020055465A1 (en) Nocathiacin antibiotics prepared by biotransformation or chemical methods
CN113004379B (en) Norfluxan and preparation method and application thereof
CN104988083A (en) Streptomyces platensis and applications of Streptomyces platensis in production of platensimycin and platencin
CN1872854A (en) Antibiotic in lactam class, and prepartion method
CN115247131B (en) Trichoderma atroviride and metabolite and application thereof
EP0413967B1 (en) Novel antibiotic
CN116836112B (en) Pyridine alkaloid and application thereof
CA2444907C (en) Substantially pure glycopeptide antibiotics ac-98-1; ac-98-2; ac-98-3; ac-98-4 and ac-98-5
Jovetic et al. Biotransformation of the lipoglycopeptide antibiotic A40926 with immobilized cells of Actinoplanes teichomyceticus-in situ supply of nutrients
CN108002999B (en) Naphthalene compound and preparation method and application thereof
CN110698541B (en) Natural Rakicidins compound Rakicidin J and fermentation extraction method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant